Vendor Intelligence Report: Wuhan Newtop Biotech

Published 13 Jun 2026. 24-page investigative report on who is behind Wuhan Newtop Biotech: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 6 Finnrick lab tests, Wuhan Newtop Biotech has 6 pass / 0 fail — an overall pass rate of 100%. That is the buyer-positive signal in this file, but it is narrow: the independent record covers only two products in a much wider catalog. Retatrutide is the better-supported Newtop choice because it has multiple independent passes; GHK-Cu is encouraging but rests on a single pass. Semaglutide and tirzepatide remain unproven by Finnrick for this vendor despite vendor-published Janoshik reports.

The corporate story is less clean than the product headline. WHOIS, marketplace, Wayback and address evidence point to a relatively new English retail storefront attached to an older Wuhan chemical-supplier footprint. The report traces how Newtop, Hubei Harvest Chemical, shared contacts, a Harvest-domain email in Newtop’s customer funnel, and a separate steroid/SARMS-domain artifact fit together — while separating high-confidence operating links from unresolved ownership claims.

The main buyer risk is not a current Finnrick failure row; it is import exposure and verification friction. Newtop’s catalog overlaps peptide categories named in a CBP seizure campaign involving 5,000+ China-origin shipments, and the report weighs customs-safety marketing against enforcement records and community reports of cosmetics declarations. The affiliate surface is comparatively quiet: the X/web sweep found no code-driven promoter network, though Telegram, Discord, TikTok and other private channels remain outside that clean bill.

Inside the full report:

  • Per-product pass/fail rates and methodology-divergence charts for all 2 tested products
  • Dated evidence timeline covering marketplace records, WHOIS, Wayback captures and UEESHOP deployment
  • Address, personnel and email-link analysis connecting Newtop with Hubei Harvest Chemical
  • Vendor-commissioned Janoshik COA review contrasted with independent Finnrick coverage gaps
  • CBP seizure-context analysis for GLP-1s and other overlapping peptide categories
  • Affiliate and promotion sweep results, plus unresolved registry, import-record and sister-brand leads

Risk assessment

  • Customs-seizure and mis-manifesting risk — high: Newtop/Harvest catalog overlaps CBP’s 5,000+ seized Chinese peptide shipments; community reports describe cosmetics declarations and buyers may face seizure or penalties.
  • Multi-brand identity and verification risk — medium: Newtop shares address/personnel/catalog signals with Hubei Harvest, uses Harvest email/changed contacts, and captured pages show no authoritative channel/reseller or anti-counterfeit framework.
  • Limited independent testing coverage across the catalog — medium: Finnrick has 6 tests, all pass, but only Retatrutide and GHK-Cu are covered; semaglutide and tirzepatide rely on vendor-selected Janoshik COAs in the supplied record.
  • Regulated-product catalog risk — medium: The catalog includes GLP-1 analogues, estrogens, veterinary drugs and other regulated chemical categories sold by a Chinese exporter with no Western corporate registration located.